BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 18952898)

  • 1. RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.
    Kim WI; Matise I; Diers MD; Largaespada DA
    Blood; 2009 Jan; 113(5):1086-96. PubMed ID: 18952898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia.
    Sachs Z; LaRue RS; Nguyen HT; Sachs K; Noble KE; Mohd Hassan NA; Diaz-Flores E; Rathe SK; Sarver AL; Bendall SC; Ha NA; Diers MD; Nolan GP; Shannon KM; Largaespada DA
    Blood; 2014 Nov; 124(22):3274-83. PubMed ID: 25316678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
    Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
    Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome.
    Stavropoulou V; Kaspar S; Brault L; Sanders MA; Juge S; Morettini S; Tzankov A; Iacovino M; Lau IJ; Milne TA; Royo H; Kyba M; Valk PJM; Peters AHFM; Schwaller J
    Cancer Cell; 2016 Jul; 30(1):43-58. PubMed ID: 27344946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heritable genetic background alters survival and phenotype of Mll-AF9-induced leukemias.
    Young K; Loberg MA; Eudy E; Schwartz LS; Mujica KD; Trowbridge JJ
    Exp Hematol; 2020 Sep; 89():61-67.e3. PubMed ID: 32768438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rac1 signaling protects monocytic AML cells expressing the MLL-AF9 oncogene from caspase-mediated apoptotic death.
    Hinterleitner C; Huelsenbeck J; Henninger C; Wartlick F; Schorr A; Kaina B; Fritz G
    Apoptosis; 2013 Aug; 18(8):963-79. PubMed ID: 23624644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis.
    Xue L; Pulikkan JA; Valk PJ; Castilla LH
    Blood; 2014 Jul; 124(3):426-36. PubMed ID: 24894773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
    Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
    Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The AAA+ ATPase RUVBL2 is a critical mediator of MLL-AF9 oncogenesis.
    Osaki H; Walf-Vorderwülbecke V; Mangolini M; Zhao L; Horton SJ; Morrone G; Schuringa JJ; de Boer J; Williams O
    Leukemia; 2013 Jul; 27(7):1461-8. PubMed ID: 23403462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.
    Chen Y; Ernst P
    Cell Cycle; 2019 Jul; 18(14):1525-1531. PubMed ID: 31161857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Id2 and E Proteins Orchestrate the Initiation and Maintenance of MLL-Rearranged Acute Myeloid Leukemia.
    Ghisi M; Kats L; Masson F; Li J; Kratina T; Vidacs E; Gilan O; Doyle MA; Newbold A; Bolden JE; Fairfax KA; de Graaf CA; Firth M; Zuber J; Dickins RA; Corcoran LM; Dawson MA; Belz GT; Johnstone RW
    Cancer Cell; 2016 Jul; 30(1):59-74. PubMed ID: 27374225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MLL-AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia.
    Manara E; Baron E; Tregnago C; Aveic S; Bisio V; Bresolin S; Masetti R; Locatelli F; Basso G; Pigazzi M
    Blood; 2014 Jul; 124(2):263-72. PubMed ID: 24695851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.
    Bilardi RA; Anstee NS; Glaser SP; Robati M; Vandenberg CJ; Cory S
    Cell Death Dis; 2016 Sep; 7(9):e2351. PubMed ID: 27584789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MLL-AF9 leukemia stem cells: hardwired or taking cues from the microenvironment?
    Muntean AG; Hess JL
    Cancer Cell; 2008 Jun; 13(6):465-7. PubMed ID: 18538728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autophagy is dispensable for Kmt2a/Mll-Mllt3/Af9 AML maintenance and anti-leukemic effect of chloroquine.
    Chen X; Clark J; Wunderlich M; Fan C; Davis A; Chen S; Guan JL; Mulloy JC; Kumar A; Zheng Y
    Autophagy; 2017 May; 13(5):955-966. PubMed ID: 28282266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SIRT2 regulates proliferation and chemotherapy response of MLL-ENL-driven acute myeloid leukemia.
    Hao C; Shao X; Song J; Peng M; Lao Y; Mack R; Zhang L; Wei W; Liu N; Wang T; Wu Y; Feng L; Yin L; Wang S; Sun X; Chen S; Zhang J; Li B
    Biochem Biophys Res Commun; 2022 Mar; 596():36-42. PubMed ID: 35108652
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Liu J; Guo B; Chen Z; Wang N; Iacovino M; Cheng J; Roden C; Pan W; Khan S; Chen S; Kyba M; Fan R; Guo S; Lu J
    Blood; 2017 Mar; 129(11):1491-1502. PubMed ID: 28053194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The E3 ubiquitin ligase Triad1 influences development of Mll-Ell-induced acute myeloid leukemia.
    Wang H; Bei L; Shah CA; Huang W; Platanias LC; Eklund EA
    Oncogene; 2018 May; 37(19):2532-2544. PubMed ID: 29459712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia.
    Wei J; Wunderlich M; Fox C; Alvarez S; Cigudosa JC; Wilhelm JS; Zheng Y; Cancelas JA; Gu Y; Jansen M; Dimartino JF; Mulloy JC
    Cancer Cell; 2008 Jun; 13(6):483-95. PubMed ID: 18538732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-terminal BRE inhibits cellular proliferation and increases sensitivity to chemotherapeutic drugs of MLL-AF9 acute myeloid leukemia cells.
    Pun CC; Lee KK; Chui YL
    Leuk Lymphoma; 2019 Dec; 60(12):3011-3019. PubMed ID: 31111759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.